Patents by Inventor Heike Zimdahl-Gelling

Heike Zimdahl-Gelling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20200046713
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: August 1, 2019
    Publication date: February 13, 2020
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20190000855
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 3, 2019
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
    Patent number: 10092571
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 9, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20160354380
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 8, 2016
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
    Patent number: 9457029
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: October 4, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
  • COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION
    Publication number: 20150147295
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 28, 2015
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION
    Publication number: 20140271544
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 18, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20130196898
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: November 26, 2010
    Publication date: August 1, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling